ArticleCardiovascular and interventional radiology2026
Intra-Arterial Chemotherapy for Advanced Intraocular Retinoblastoma….
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety and efficacy of intra-arterial chemotherapy as a treatment for advanced intraocular retinoblastoma and to present our single-center experience. MATERIALS AND
methodsThis single-center retrospective cohort study included 13 pediatric patients (15 eyes) who underwent intra-arterial chemotherapy between January 2020 and December 2024. Patients were categorized into two groups: those receiving treatment as a first-line option (group 1) and those treated following the failure of previous therapies (group 2). Data were collected on technical success, complications, ocular preservation, and visual function. Each patient was monitored for a minimum of 12 months after treatment initiation.
resultsAccording to the ICRB classification, most eyes (66.7%) were Groups D, followed by groups C and E. The mean age at presentation was 22.5 months. A total of 45 intra-arterial chemotherapy procedures were performed, with successful catheterization achieved in 97.8% of cases. Minor procedural complications were observed in 8.8% of sessions, with no serious systemic adverse events. Visual acuity was maintained or improved in 93.3% of treated eyes. No patients required enucleation, and no cases of metastasis or death occurred during follow-up.
conclusionIntra-arterial chemotherapy is a technically feasible and promising globe-sparing treatment for intraocular retinoblastoma, demonstrating high technical success and a favorable safety profile in our cohort. While preliminary outcomes show preserved visual function and high ocular survival, larger studies with longer follow-up are necessary to confirm long-term efficacy and safety within a multidisciplinary framework.
Indexed as
Identifiers
41984109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.